arrow
P

Peter A. Kaufman

Department of Medicine
H指数:60
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: a systematic literature review of real-world evidence

曲拉曲坦在HER2阳性晚期/转移性乳腺癌患者中的应用:一项真实世界证据的系统文献综述

2026-06-090
OAAI
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

乳腺癌管理中的争议与关键知识空白专家观点:第一届弥合乳腺癌知识空白研讨会的会议录

2025-04-080
PRE
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
2024-10-080
OAAI
Abemaciclib plus fulvestrant for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial

Abemaciclib联合fulvestrant用于既往接受过CDK4/6抑制剂联合内分泌治疗进展后的HR+、HER2-晚期乳腺癌:postMONARCH III期试验的亚组分析

2024-09-011
PRE
Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
2024-05-021
PRE
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Abemaciclib单独或与内分泌治疗在晚期乳腺癌中循环肿瘤DNA的基线和获得性基因组改变的前景

2023-10-274
OAAI
Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
2023-03-017
PRE